Cipla

Cipla
Name	Cipla
Type	Public
Founded	1935
Founders	Khwaja Abdul Hamied
Headquarters	Mumbai
Industry	Pharmaceuticals
Products	Pharmaceuticals, Active pharmaceutical ingredients

Contents

Cipla is an Indian multinational pharmaceutical and biotechnology company founded in 1935 by Khwaja Abdul Hamied with headquarters in Mumbai. It is known for manufacturing generic drugs, active pharmaceutical ingredients, and formulations for conditions including respiratory diseases, cardiovascular disorders, and HIV/AIDS; its activities span regulatory engagement with agencies such as the U.S. Food and Drug Administration, the European Medicines Agency, and the Drug Controller General of India. The company has been involved in major industry events including patent disputes linked to Novartis and access campaigns associated with Médecins Sans Frontières and the Bill & Melinda Gates Foundation.

History

Cipla was established in 1935 by Khwaja Abdul Hamied in Mumbai during the late colonial period of British India and expanded operations through the Indian independence movement and post-independence industrialization under leaders like Yusuf Khwaja Hamied. The firm grew through manufacturing ties with early partners and manufacturers from Germany and Switzerland and navigated regulatory frameworks set by the Indian Council of Medical Research and the Reserve Bank of India. In the late 20th and early 21st centuries Cipla engaged with multinational corporations such as GlaxoSmithKline, Pfizer, and Roche in licensing, litigation, and market competition, and it featured in public debates about intellectual property following the TRIPS Agreement and actions by the World Trade Organization. Strategic acquisitions and expansions occurred amid mergers and acquisitions activity across Asia and Africa involving companies like Matrix Laboratories and negotiations with entities in South Africa and Brazil.

Cipla operates manufacturing facilities in multiple Indian states, export hubs linked to ports in Mumbai and Kochi, and supply chains that interact with distributors such as AmerisourceBergen and Mylan. Its product portfolio encompasses inhalers and respiratory medicines similar to those of Boehringer Ingelheim and AstraZeneca, antiretroviral combinations used by programs led by UNAIDS and WHO, cardiovascular agents comparable to offerings from Bayer and Sanofi, and APIs for companies including Sun Pharmaceutical Industries and Dr. Reddy's Laboratories. The company sells generics, over-the-counter products, biosimilars, and sterile injectables, and competes in markets served by firms such as Teva Pharmaceutical Industries and Johnson & Johnson. Its quality control and compliance activities respond to inspections by regulators including the U.S. Food and Drug Administration, the Medicines and Healthcare products Regulatory Agency, and national agencies in Nigeria and Kenya.

Cipla maintains R&D centers that collaborate with academic institutions like Indian Institute of Technology Bombay, Jawaharlal Nehru University, and clinical research networks tied to hospitals such as All India Institute of Medical Sciences. Research efforts encompass formulation science, process chemistry, and development of fixed-dose combinations informed by guidelines from World Health Organization technical programs and pharmacopoeias issued by the United States Pharmacopeia and the British Pharmacopoeia. The company has engaged in collaborations and licensing with biotechnology firms and research funders such as the Wellcome Trust and the Bill & Melinda Gates Foundation, and participates in clinical trials registered with authorities like the Clinical Trials Registry - India and databases overseen by the U.S. National Institutes of Health. Cipla’s R&D strategy addresses challenges highlighted in debates involving Intellectual Property Rights under the TRIPS Agreement and technology transfer dialogues involving World Trade Organization members.

Corporate governance at the company follows listing and disclosure requirements of the Bombay Stock Exchange and the National Stock Exchange of India, and interacts with institutional shareholders including pension funds from Canada Pension Plan Investment Board and asset managers like Vanguard Group and BlackRock. The board structure and executive leadership operate amid oversight frameworks inspired by standards set in the Companies Act, 2013 and corporate governance codes promoted by the Securities and Exchange Board of India. Significant family involvement traces to the founder’s descendants, and corporate actions have been shaped by shareholder resolutions, proxy advisory input from Institutional Shareholder Services, and engagement with investor forums such as CII and NASSCOM where applicable.

Cipla’s international footprint spans markets in Africa, Latin America, Europe, and Asia with subsidiaries and joint ventures in countries including South Africa, Uganda, Brazil, and United Kingdom. It has established procurement and distribution partnerships with multilateral organizations such as United Nations Children's Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria, and bilateral programs coordinated with ministries of health in Kenya and Mozambique. Strategic alliances and licensing arrangements have linked Cipla to firms like Mylan, Aurobindo Pharma, and research collaborations with academic centers such as University of Oxford and Imperial College London. The company has also participated in global price negotiations and access initiatives alongside advocacy groups like Treatment Action Campaign and Clinton Health Access Initiative.

Cipla has engaged in CSR activities focused on access to medicines, collaborating with organizations such as Doctors Without Borders (Médecins Sans Frontières), Clinton Health Access Initiative, and the Bill & Melinda Gates Foundation to expand availability of antiretrovirals and treatments for tuberculosis and respiratory illness. Programs have involved partnerships with national health programs in India, South Africa, and Kenya, and have been discussed in forums hosted by World Health Organization, UNAIDS, and civil society networks including Treatment Action Campaign. CSR initiatives include support for patient assistance through NGOs like PATH and community health projects linked to institutions such as All India Institute of Medical Sciences and regional public health departments.

Category:Pharmaceutical companies of India